EU/3/16/1649

About

Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2020 on request of the sponsor.

On 28 April 2016, orphan designation (EU/3/16/1649) was granted by the European Commission to Abbvie Ltd, United Kingdom, for humanised recombinant IgG4 anti-human tau antibody (also known as ABBV-8E12) for the treatment of progressive supranuclear palsy.

The sponsorship was transferred to AbbVie Deutschland GmbH & Co. KG, Germany, in May 2018.

This medicine is now known as tilavonemab.

Key facts

Active substance
Humanised recombinant IgG4 anti-human tau antibody (tilavonemab)
Disease / condition
Treatment of progressive supranuclear palsy
Date of first decision
28/04/2016
Outcome
Withdrawn
EU designation number
EU/3/16/1649

Review of designation

Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2020 on request of the sponsor.

Sponsor's contact details

AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen am Rhein
Tel. +44 1628 925033
E-mail: eu-orphan-drug@abbvie.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating